Phathom Pharmaceuticals, Inc. PHAT Non Cash Final Interest Payment Fee
Non Cash Final Interest Payment Fee at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept phat:NonCashFinalInterestPaymentFee.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s non cash final interest payment fee.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s non cash final interest payment fee?
- Phathom Pharmaceuticals, Inc. (PHAT) reported non cash final interest payment fee of $3.5M in Q1 2026.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s non cash final interest payment fee?
- Over 2 years (2021 to 2025), Phathom Pharmaceuticals, Inc.'s non cash final interest payment fee has grown at a -100.0% compound annual growth rate (CAGR), from $7.5M to $0.
- What does non cash final interest payment fee mean?
- This represents non-cash charges or adjustments related to final interest payments or fees associated with debt instruments. It captures the accounting impact of financing costs that do not involve immediate cash outflows. Understanding these non-cash items is critical for reconciling net income to actual operating cash flow.